Company Filing History:
Years Active: 2019-2022
Title: Oi Kwan Wong: Innovator in Cancer Treatment
Introduction
Oi Kwan Wong is a notable inventor based in Belmont, CA (US), recognized for his contributions to the field of cancer treatment. He holds a total of 4 patents that focus on innovative therapeutic methods targeting specific cancer-related proteins.
Latest Patents
Wong's latest patents include groundbreaking inventions such as antibodies specific for epidermal growth factor receptor variant III (EGFRvIII) and their uses. This invention provides antibodies that specifically bind to EGFRvIII, along with bispecific antibodies that target both EGFRvIII and another antigen, such as CD3. Additionally, it encompasses antibody conjugates and methods for obtaining these antibodies, which are crucial for treating EGFRvIII-mediated pathologies, including glioblastoma. Another significant patent involves Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII. This invention relates to engineered immune cells that incorporate these CARs, along with CAR-encoding nucleic acids, and therapeutic methods for utilizing these engineered immune cells in treating cancers like glioblastoma.
Career Highlights
Oi Kwan Wong is currently employed at Pfizer Corporation, where he continues to advance his research and development efforts in the field of oncology. His work has significantly contributed to the understanding and treatment of various cancers, particularly those associated with EGFRvIII.
Collaborations
Wong collaborates with esteemed colleagues such as Joyce Ching Chou and Barbra Johnson Sasu, who contribute to his innovative projects and research initiatives.
Conclusion
Oi Kwan Wong's innovative work in developing targeted therapies for cancer exemplifies the impact of scientific research on medical advancements. His patents and collaborations continue to pave the way for new treatment options in oncology.